Exact Sciences Inc. (EXAS) - Gross Profit Ratio

Stable demand for non-invasive diagnostics and insurance coverage for Cologuard create a solid business foundation for Exact Sciences (EXAS). Historical gross margins illustrate this efficiency, with 69.70 representing the current metric. High-margin screening tests that reduce mortality support profit growth, while strategic partnerships with oncology centers and biopharmaceutical companies accelerate the expansion of Exact Sciences (EXAS) in the field of early cancer detection.
Financial and market metric breakdowns for exactsciences.com (EXAS)

Gross margin measures production efficiency by determining the profit share remaining after covering direct costs. By analyzing the gross margin chart on GURU.Markets, an investor assesses the ability of Exact Sciences (EXAS) management to pass inflation onto customers. This metric is sensitive to the cost of services and reflects the business's fundamental margin of safety. The stability of this indicator is supported by the optimization of a unique biosample collection system and high-speed laboratory processing.